Methods of stimulating hematopoietic cells with flt3-ligand
AssigneeImmunex Corporation
InventorsStewart D. Lyman, M. Patricia Beckmann
Life of this patent
Estimating the term…
Abstract
Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.
Claims17
A method for stimulating the proliferation of hemapoeitic stem or progenitor cells in a patient in need thereof, comprising administering a hemapoeitic stem or progenitor cell-stimulating amount of a human flt3-L polypeptide, and optionally, a hemapoeitic stem or progenitor cell-stimulating amount of at least one growth factor selected from the group consisting of CSF-1, GM-CSF, SF, G-CSF, EPO, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, GM-CSF/IL-3 fusion proteins, LIF and FGF.
A method for stimulating the proliferation of hemapoeitic stem or progenitor cells in a patient having symptoms of myelodysplastic syndrome, comprising administering a hemapoeitic stem or progenitor cell-stimulating amount of a human flt3-L polypeptide, and optionally, a hemapoeitic stem or progenitor cell-stimulating amount of at least one growth factor selected from the group consisting of CSF-1, GM-CSF, SF, G-CSF, EPO, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, GM-CSF/IL-3 fusion proteins, LIF and FGF.
A method for stimulating the proliferation of hemapoeitic stem or progenitor cells in a patient having symptoms of anemia, comprising administering a hemapoeitic stem or progenitor cell-stimulating amount of a human flt3-L polypeptide, and optionally, a hemapoeitic stem or progenitor cell-stimulating amount of at least one growth factor selected from the group consisting of CSF-1, GM-CSF, SF, G-CSF, EPO, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, GM-CSF/IL-3 fusion proteins, LIF and FGF.
A method for stimulating the proliferation of hemapoeitic stem or progenitor cells in a patient having symptoms of acquired immune deficiency syndrome, comprising administering a hemapoeitic stem or progenitor cell-stimulating amount of a human flt3-L polypeptide, and optionally, a hemapoeitic stem or progenitor cell-stimulating amount of at least one growth factor selected from the group consisting of CSF-1, GM-CSF, SF, G-CSF, EPO, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, GM-CSF/IL-3 fusion proteins, LIF and FGF.
An improved method for conducting autologous transplantation in a patient receiving cytoreductive therapy, the method comprising:
- (a) collecting hematopoietic progenitor or stem cells from the patient prior to receipt of cytoreductive therapy;
- and
- (b) administering such collected cells to the patient after receipt of cytoreductive therapy;
- wherein the improvement comprises the step of administering an effective amount of human flt3-L to the patient prior to the cell collection of step (a) to increase the number of circulating progenitor cells or stem cells available for collection.
An improved method for conducting autologous transplantation in a patient receiving cytoreductive therapy, the method comprising:
- (a) collecting hematopoietic progenitor or stem cells from the patient prior to receipt of cytoreductive therapy;
- and
- (b) administering such collected cells to the patient after receipt of cytoreductive therapy;
- wherein the improvement comprises the step of contacting said collected progenitor cells or stem cells ex vivo with an effective amount of human flt3-L prior to administering such collected cells to the patient after receipt of cytoreductive therapy.
An improved method for conducting autologous transplantation in a patient receiving cytoreductive therapy, the method comprising:
- (a) collecting hematopoietic progenitor or stem cells from the patient prior to receipt of cytoreductive therapy;
- and
- (b) administering such collected cells to the patient after receipt of cytoreductive therapy;
- wherein the improvement comprises the step of administering an effective amount of human flt3-L to the patient after receipt of cytoreductive therapy to facilitate the engraftment of the progenitor or stem cells in the patient.
A method of stimulating the proliferation of T cells in a mammal comprising administering to the mammal an effective amount of a human flt3-L polypeptide.
A method of stimulating the proliferation of cells of the erythroid lineage in the spleen of a mammal comprising administering to the mammal an effective amount of a human flt3-L polypeptide.
Dependencies are inferred from the claim text.